CHNA
Loncar China BioPharma ETF
CHNA
CHNA
Delisted
CHNA was delisted on the 20th of October, 2023.
3 hedge funds and large institutions have $30K invested in Loncar China BioPharma ETF in 2022 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 2 reducing their positions, and 1 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
3
Holders Change
-1
Holders Change %
-25%
% of All Funds
0.05%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
–
Reduced
2
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–
Top Buyers
No buyers this quarter
Top Sellers
| 1 |
Jane Street
New York
|
-$1.64M |
| 2 |
Morgan Stanley
New York
|
-$42.6K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$5.79K |
| Name | Holding | Trade Value |
Shares Change |
Shares Change % |
|
|---|---|---|---|---|---|
|
1
UBS Group
Zurich,
Switzerland
| $17K | -$5.79K | -278 | -25% |
|
|
BBPWM
2
Blue Bell Private Wealth Management
Blue Bell,
Pennsylvania
| $9K | – | – | – |
|
|
3
Morgan Stanley
New York
| $4K | -$42.6K | -2,000 | -91% |
|
|
4
Jane Street
New York
| – | -$1.64M | -61,266 | Closed |
|